MDxHealth

MDXH

Market cap $173M

Mdxhealth Highlights Data from Oxford's ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026

MDxHealth SA (MDXH) Q4 2025 Earnings Call Transcript

Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26 Company to Host Conference Call with Live Q&A, February 26, 2026, at 4:30pm ET / 22:30 CET IRVINE, California – February 12, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2025, after market close on Thursday, February 26, 2026. Title: Mdxhealth Presents Fourth Quarter and Full Year 2025 Financial Results andCorporate Update Conference Call and Webcast Date: February 26, 2026 Time: 4:30pm ET/ 22:30 CET Conference Call D ial-in Details: United States: 1-844-825-9789 Int'l: 1-412-317-5180 Belgium: 0800 38 961 United Kingdom: 0800 279 9489 Conference ID:         10206764 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1753070&tp_key=27bce7d4de The webcast should be accessed 15 minutes prior to the conference call start time.

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences

Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer

MDxHealth SA ( MDXH ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Michael McGarrity - CEO & Executive Director Scott McMahan - Vice President of Finance and Accounting Conference Call Participants John Fraunces - Lifesci Advisors, LLC Daniel Brennan - TD Cowen, Research Division Andrew Brackmann - William Blair & Company L.L.C., Research Division William Bonello - Craig-Hallum Capital Group LLC, Research Division Mark Massaro - BTIG, LLC, Research Division Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the MDxHealth Third Quarter 2025 Earnings Conference Call.

If you are looking for stocks that are well positioned to maintain their recent uptrend, MDxHealth SA (MDXH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Appointment of Executive Chairman, proposed change of name and strategy update Company to pursue revised strategy and name change to CelLBxHealth plc Dr. Jan Groen, the current Non-Executive Chairman and recognised oncology diagnostic industry veteran, to lead company as Executive Chairman Revised strategy to sharpen focus on the provision of industry-leading CTC intelligence and accelerate Company's commercial traction, whilst delivering further cost control Cash runway remains through to Q1 2026; expected need to raise funds in coming months GUILDFORD, SURREY / ACCESS Newswire / October 8, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a global precision CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that its Chairman, Dr Jan Groen, has moved into an executive role. Jan will lead the Company as it pursues a revised strategy, focused on tight cost control, accelerated commercial progress and a clear plan towards becoming a sustainable business.

MDxHealth SA (MDXH) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.31 per share a year ago.

M dxh ealth Reports Preliminary Second Quarter 202 5 Results , Reaches Positive Adjusted EBITDA , and A nnounces Acquisition of Exo some D iagnostics B usiness from Bio - Techne